Kristen Williams - Jun 9, 2021 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role: Chief Administrative Officer
Signature: /s/ Kristen Williams
Stock symbol: PCRX
Transactions as of: Jun 9, 2021
Transactions value $: -$339,063
Form type: 4
Date filed: 6/11/2021, 08:38 PM
Previous filing: Jun 8, 2021
Next filing: Jan 20, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCRX	Common Stock	Award	$0	+7K	+33.4%	$0.00	28K	Jun 9, 2021	Direct	F1
transaction	PCRX	Common Stock	Sale	-$288K	-4.84K	-17.32%	$59.43	23.1K	Jun 10, 2021	Direct	F2, F3
transaction	PCRX	Common Stock	Sale	-$51.3K	-847	-3.66%	$60.57	22.3K	Jun 10, 2021	Direct	F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PCRX	Stock Option (Right to Buy)	Award	$0	+17.5K		$0.00	17.5K	Jun 9, 2021	Common Stock	17.5K	$60.96	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2022, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.03 to $59.99, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 and 4.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.20 to $60.92, inclusive.
F5	The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.